Rgenta Therapeutics
Thomas Wynn has a diverse work experience spanning various positions in the pharmaceutical and biotech industry. Thomas is currently working as the Director of Medicinal Chemistry at Rgenta Therapeutics Inc., a position they have held since 2023. Prior to this, Thomas owned their own consulting firm, WynnChem Consulting LLC, where they provided medicinal chemistry advice and guidance to biotech clients. Thomas also advised drug discovery software startups on product usability and marketability.
Before their consulting role, Thomas served as the Scientific Director at Ikena Oncology, where they co-led a program and delivered multiple novel chemical series for a structurally enabled project. Thomas also contributed to the progression of other internal discovery programs and strengthened the company's discovery chemistry infrastructure.
Thomas has previously worked as the Director of Medicinal Chemistry at Accent Therapeutics, Inc., where they were involved in drug hunting partnerships and managed relationships with external partners. Thomas also worked as a Senior Principal Scientist at TESARO, Inc., where they identified and vetted oncology targets in the Strategic Drug Hunting Partnerships group and aided in business development.
Thomas has also held positions at Alkermes, Brandeis University, Biogen, Pfizer Research Technology Center, and Pharmacia, where they gained experience in leading discovery stage projects, managing research teams, and designing and synthesizing novel compounds.
Overall, Thomas Wynn has a strong background in medicinal chemistry, drug discovery, and research leadership, with a proven track record of success in both industry and consulting roles.
Thomas Wynn completed their B.S. in Chemistry at the Georgia Institute of Technology from 1990 to 1994. Thomas then pursued a Doctor of Philosophy (PhD) in Synthetic Organic Chemistry at Colorado State University, graduating in 1999. Following this, from 2000 to 2002, they undertook a Post Doc in Synthetic Chemistry at the University of Illinois Urbana-Champaign.
Rgenta Therapeutics
Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders.